Auriga
Auriga USA is a research and trading platform that focuses on growth sectors within the Health Care and Technology verticals. We operate out of our main office in New York City, and also have satellite offices in Boston, San Francisco, Philadelphia, San Diego, and Washington D.C. This regional network helps us to keep abreast of key corporate developments, enhance client relationships, and provide more efficient product distribution to meet clients' investment needs. The firm is committed to providing our clients with critical information flow, investment ideas, and access to industry experts.
-
Auriga Maintains a 'Buy' on Altera (ALTR); Near term Weakness but Longer Term Trends Intact
-
Notable Analyst Rating Changes 04/13: (GTXI) (ALTR) (IRBT) Upgraded; (SUN) (MT) (LEDS) Downgraded
-
Auriga Assumes Coverage on Xilinx (XLNX) at Buy; Near-Term Risk, but Longer-Term Prospects Remain Attractive
-
Auriga Assumes Coverage and Upgrades Altera (ALTR) to Buy; Expecting Growth to Resume in 2H11
-
Auriga Maintains a 'Buy' on Xilinx (XLNX); Analyst Day Increases Our Conviction in 28nm Potential
-
Auriga Prefers Xilinx's (XLNX) Over Altera (ALTR) on Valuation and Potential Operating Leverage
-
Auriga Upgrades Xilinx (XLNX) to Buy, Price Target $37
-
Auriga Maintains a 'Hold' on Xilinx (XLNX); Weakness Likely Driven by Inventory Correction in Wireless
-
Auriga Lowers Estimates on Altera (ALTR), Raises Price Target to $37
-
Daily State of the Markets 11/30: A Defensive Stand, But...
-
Notable Analyst Rating Changes 10/01: PLXS, ACN, ETN, LCRY Upgraded; JASO, DE, NFLX, CAT Downgraded
-
Auriga Starts Altera (ALTR) at Hold, Citing Cyclical Concerns

